DRMAW
Dermata Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−50.00%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-239.9%
Return on equity
-157.3%
Return on assets
-246.6%
Return on invested capital
0.00x
Asset turnover
-$8.0M
Cash from operations
$4.30
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026